• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » GamaMabs Pharma raises €15m in series B financing round

GamaMabs Pharma raises €15m in series B financing round

December 15, 2015
CenterWatch Staff

GamaMabs Pharma, a Toulouse, France-based biotechnology company developing optimized therapeutic antibodies for the treatment of cancer, today announced the completion of a €15 million ($15.9 million) series B financing round.

The round was led by a new investor, BioDiscovery 4, a fund managed by Edmond de Rothschild Investment Partners (EdRIP). All existing GamaMabs investors (InnoBio, Irdinov, Alto Invest and iXO Private Equity) also subscribed to the round. The company raised €3.6 million ($3.8 million) in 2013 in a series A funding round led by InnoBio (Bpifrance).

The fundraising will primarily fund the phase I and phase II clinical trials of GM102 (3C23K), a monoclonal antibody targeting gynecological cancers. GM102 is a first-in-class antibody and the company’s most advanced product. It targets AMHRII, a protein expressed on tumor cells’ membrane surface in various gynecological cancers. It also activates immune cells present in the tumor microenvironment. The first-in-man clinical trials of GM102 will start in the first half of 2016.

“We are thrilled to welcome EdRIP, a high-profile investor that supports our goal to build GamaMabs into a market leader specialized in the treatment of gynecological cancers,” said Philippe Boucheron, deputy director of life sciences at Bpifrance Investissement. “The company is now well-equipped to demonstrate the clinical benefits of its products.”

"We are delighted with the trust expressed by EdRIP and all our current investors. This fundraising will fund proof-of-concept clinical trials on our GM102 antibody in patients with recurrent gynecologic cancers which represent major unmet medical needs,” said GamaMabs CEO Stéphane Degove.

“This financing concludes a very positive year for GamaMabs, including successfully completed GM102 preclinical trials, demonstrating its very favorable efficacy-safety profile,” said Dr. Jean-François Prost, vice president of R&D and strategy at GamaMabs.

Following the fundraising, Gilles Nobécourt, partner at EdRIP, and Professor Thierry Hercend will join GamaMabs’ board of directors.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing